Private Advisory Group LLC Acquires New Shares in Intuitive Surgical, Inc. $ISRG

Private Advisory Group LLC acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,897 shares of the medical equipment provider’s stock, valued at approximately $9,717,000.

Other hedge funds have also made changes to their positions in the company. Fairscale Capital LLC lifted its holdings in shares of Intuitive Surgical by 3.5% during the 3rd quarter. Fairscale Capital LLC now owns 645 shares of the medical equipment provider’s stock valued at $279,000 after acquiring an additional 22 shares in the last quarter. Beaumont Financial Advisors LLC increased its holdings in Intuitive Surgical by 3.8% in the 3rd quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 23 shares in the last quarter. Hughes Financial Services LLC increased its holdings in Intuitive Surgical by 40.7% in the 3rd quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 24 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in Intuitive Surgical by 1.0% in the 1st quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after purchasing an additional 25 shares in the last quarter. Finally, Blue Fin Capital Inc. raised its position in Intuitive Surgical by 0.5% in the first quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research reports. Stifel Nicolaus cut their price objective on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research report on Friday, July 17th. Leerink Partners set a $503.00 target price on Intuitive Surgical and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. TD Cowen reiterated a “buy” rating and issued a $485.00 target price on shares of Intuitive Surgical in a research note on Monday, October 19th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $486.00 target price (down from $487.00) on shares of Intuitive Surgical in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $493.54.

Insider Transactions at Intuitive Surgical

In other news, Director Gary S. Guthart sold 20,095 shares of the firm’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $451.61, for a total transaction of $9,075,102.95. Following the completion of the sale, the director directly owned 1,204,530 shares in the company, valued at $543,977,793.30. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $458.15, for a total value of $183,260.00. Following the sale, the executive vice president directly owned 6,236 shares in the company, valued at approximately $2,857,023.40. The trade was a 6.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,456 shares of company stock worth $17,769,124 over the last three months. Insiders own 0.60% of the company’s stock.

Intuitive Surgical Trading Down 2.1%

Shares of ISRG stock opened at $439.89 on Friday. The company has a market capitalization of $152.48 billion, a PE ratio of 53.19, a price-to-earnings-growth ratio of 3.10 and a beta of 1.45. The firm has a fifty day simple moving average of $416.12 and a 200-day simple moving average of $430.38. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same period last year, the business earned $2.40 EPS. The business’s revenue was up 21.7% on a year-over-year basis. Equities research analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.